miRNA-324, a potential therapeutic target for paracetamol-induced liver injury

Abstract

Paracetamol is one of the most widely used medications for relieving pain and fever. When taken in the therapeutic doses, paracetamol is predominantly metabolized in the liver via conjugation reaction by phase II drug metabolizing enzymes such as sulfotransferases and glucuronyl transferases, and is removed from the body without liver damage (1). However, when paracetamol is taken in excessive doses, it is bioactivated by phase I enzymes (e.g., CYP3A4 and CYP2E1) to generate a toxic intermediate N-acetyl-p-benzoquinone imine (NAPQI). Rapid generation of NAPQI can lead to the depletion of intrahepatic glutathione and result in hepatocyte death and liver injury (2). Thus, hepatotoxicity elicited by paracetamol overdose is the most common cause of poisoning-related deaths (3). In other studies, overdose of paracetamol accounted for the highest proportion of cases of acute liver failure in many developed countries, resulting in death or liver transplantation (4,5). Currently, N-acetylcysteine (NAC) is the mainstay strategy in treating hepatotoxicity following paracetamol overdose. However, oral and intravenous NAC treatment has limitations because of adverse effects (6,7). Thus, identifying new therapeutic targets would be of help for clinical remedy of paracetamol overdose-related liver injury.Numerous studies have been conducted on the expression and function of drug-metabolizing enzymes (DMEs), and the information was applied for better understanding and prediction of drug responses in patients (8). Moreover, identification of novel regulators of DMEs is critical to supply more information for clinical applications. In a recent issue of Stem Cells Transl Med, Hay and colleagues have identified that inhibition of a novel noncoding RNA can reduce paracetamol-induced liver toxicity (9). The authors demonstrated that miRNA-324-5p regulates phase II drug metabolism and that the inhibitor of miRNA-324-5p can promote nontoxic metabolism of paracetamol. This finding has the potential to help clinical research in identifying future therapeutic strategy for paracetamolinduced toxicity.To examine hepatocyte biology in vitro, immortalized human hepatocytes have been developed since they are the most physiologically relevant to human liver in drug response (10). However, some limitations such as karyotypic instability and poor function exist in the derived cell lines, thus preventing their further application (10). Previously, Hay et al. have used human embryonic stem cells (hESCs) to generate human hepatocyte-like cells (hHLCs) using a serum-free-based procedure (11), which has been proved to be scalable and more primary in nature and is promising in modeling human drug metabolism and toxicity. In the current research, according to the established methodology, hESCs were differentiated to hHLCs through 18 days of culture, as indicated by the appropriate cell morphology, gene expression, and appreciable levels of metabolic function (9). Hay et al. compared hHLCs with adult human hepatocytes and confirmed the gene expression p...

Altered expression of microRNA‑92b‑3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression

“…miRNAs can directly bind the 3′-untranslated region of target genes leading to inhibition in gene expression ( 11 ). Emerging studies report that miRNAs serve important regulatory roles in tumor progression making them potential therapeutic targets in various human cancers, such as lung and liver cancer ( 12 , 13 ). Notably, some aberrantly expressed miRNAs have also been detected in PCa, such as miR-215-5p ( 14 ) and miR-145 ( 15 ), which participate in disease pathogenesis and are associated with the prognosis of PCa.…”